Edesa Biotech (EDSA) Competitors $1.96 +0.10 (+5.11%) As of 06/12/2025 03:59 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock EDSA vs. QNCX, IPSC, KRON, VTVT, ARTV, RNXT, CELU, PEPG, MRSN, and BLUEShould you be buying Edesa Biotech stock or one of its competitors? The main competitors of Edesa Biotech include Quince Therapeutics (QNCX), Century Therapeutics (IPSC), Kronos Bio (KRON), vTv Therapeutics (VTVT), Artiva Biotherapeutics (ARTV), RenovoRx (RNXT), Celularity (CELU), PepGen (PEPG), Mersana Therapeutics (MRSN), and bluebird bio (BLUE). These companies are all part of the "pharmaceutical products" industry. Edesa Biotech vs. Its Competitors Quince Therapeutics Century Therapeutics Kronos Bio vTv Therapeutics Artiva Biotherapeutics RenovoRx Celularity PepGen Mersana Therapeutics bluebird bio Quince Therapeutics (NASDAQ:QNCX) and Edesa Biotech (NASDAQ:EDSA) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their community ranking, institutional ownership, analyst recommendations, earnings, valuation, profitability, risk, dividends and media sentiment. Which has higher earnings and valuation, QNCX or EDSA? Edesa Biotech is trading at a lower price-to-earnings ratio than Quince Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioQuince TherapeuticsN/AN/A-$31.39M-$1.39-0.86Edesa BiotechN/AN/A-$6.17M-$1.59-1.23 Do insiders & institutionals hold more shares of QNCX or EDSA? 30.8% of Quince Therapeutics shares are owned by institutional investors. Comparatively, 5.5% of Edesa Biotech shares are owned by institutional investors. 20.3% of Quince Therapeutics shares are owned by insiders. Comparatively, 22.6% of Edesa Biotech shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Does the MarketBeat Community believe in QNCX or EDSA? Edesa Biotech received 18 more outperform votes than Quince Therapeutics when rated by MarketBeat users. However, 90.91% of users gave Quince Therapeutics an outperform vote while only 77.78% of users gave Edesa Biotech an outperform vote. CompanyUnderperformOutperformQuince TherapeuticsOutperform Votes1090.91% Underperform Votes19.09%Edesa BiotechOutperform Votes2877.78% Underperform Votes822.22% Is QNCX or EDSA more profitable? Quince Therapeutics' return on equity of -53.27% beat Edesa Biotech's return on equity.Company Net Margins Return on Equity Return on Assets Quince TherapeuticsN/A -53.27% -22.73% Edesa Biotech N/A -233.69%-124.14% Do analysts prefer QNCX or EDSA? Quince Therapeutics presently has a consensus price target of $8.00, suggesting a potential upside of 566.67%. Edesa Biotech has a consensus price target of $21.00, suggesting a potential upside of 974.17%. Given Edesa Biotech's higher probable upside, analysts clearly believe Edesa Biotech is more favorable than Quince Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Quince Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.29Edesa Biotech 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk & volatility, QNCX or EDSA? Quince Therapeutics has a beta of 0.8, suggesting that its share price is 20% less volatile than the S&P 500. Comparatively, Edesa Biotech has a beta of 0.41, suggesting that its share price is 59% less volatile than the S&P 500. Does the media refer more to QNCX or EDSA? In the previous week, Quince Therapeutics and Quince Therapeutics both had 2 articles in the media. Edesa Biotech's average media sentiment score of 1.44 beat Quince Therapeutics' score of 0.63 indicating that Edesa Biotech is being referred to more favorably in the news media. Company Overall Sentiment Quince Therapeutics Positive Edesa Biotech Positive SummaryQuince Therapeutics beats Edesa Biotech on 10 of the 15 factors compared between the two stocks. Get Edesa Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for EDSA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EDSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EDSA vs. The Competition Export to ExcelMetricEdesa BiotechPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$13.73M$6.92B$5.61B$8.62BDividend YieldN/A2.55%5.28%4.17%P/E Ratio-1.058.6727.2119.96Price / SalesN/A262.53408.49157.63Price / CashN/A65.8538.2534.64Price / Book10.866.597.074.69Net Income-$6.17M$143.75M$3.23B$248.14M7 Day Performance6.83%0.68%0.68%0.91%1 Month Performance-2.25%11.93%9.59%5.71%1 Year Performance-55.26%4.33%32.02%14.71% Edesa Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EDSAEdesa Biotech3.3677 of 5 stars$1.96+5.1%$21.00+974.2%-56.3%$13.73MN/A-1.0520Positive NewsShort Interest ↓Gap UpQNCXQuince Therapeutics3.672 of 5 stars$1.17flat$8.00+583.8%+67.8%$53.20MN/A-0.9460News CoverageIPSCCentury Therapeutics2.5473 of 5 stars$0.63+1.7%$4.20+570.1%-81.6%$53.10M$114.90M-0.34170Positive NewsKRONKronos Bio3.3271 of 5 stars$0.87-0.2%$1.63+86.8%-31.3%$53.04M$9.19M-0.61100Short Interest ↑VTVTvTv Therapeutics1.7111 of 5 stars$16.10-1.3%$35.50+120.5%-24.8%$51.44M$17K-3.559Positive NewsARTVArtiva Biotherapeutics2.6697 of 5 stars$2.11+0.5%$19.40+819.4%N/A$51.41M$251K0.0081Analyst UpgradeAnalyst RevisionRNXTRenovoRx2.9931 of 5 stars$1.37-1.4%$7.25+429.2%+16.2%$50.10M$240K-2.406Positive NewsShort Interest ↓CELUCelularity0.5447 of 5 stars$1.98-4.8%N/A-45.7%$49.81M$54.22M-0.75220PEPGPepGen2.7599 of 5 stars$1.52+1.3%$7.67+404.4%-91.7%$49.08MN/A-0.5130Trending NewsGap DownMRSNMersana Therapeutics4.1553 of 5 stars$0.39+1.3%$5.20+1,230.6%-84.0%$48.71M$34.01M-0.64150BLUEbluebird bio3.4099 of 5 stars$4.97flat$44.60+797.4%N/A$48.67M$103.95M-0.13520Positive News Related Companies and Tools Related Companies QNCX Competitors IPSC Competitors KRON Competitors VTVT Competitors ARTV Competitors RNXT Competitors CELU Competitors PEPG Competitors MRSN Competitors BLUE Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EDSA) was last updated on 6/13/2025 by MarketBeat.com Staff From Our PartnersElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredCollect $7k per month from Tesla’s SECRET dividendI just uncovered a strategy that could pay out up to $7,013 every month—without needing a traditional dividend...Investors Alley | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Edesa Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Edesa Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy EDSA Stock Free EDSA Stock Alerts